

Description

EPO mRNA encodes the human erythropoietin (EPO) protein, a hormone that controls erythropoiesis, or red blood cell production. EPO also plays a role in wound healing and the brain's response to neural injury. Kariko et al. showed that transfection of EPO mRNA *in vivo* resulted in significant increases of both reticulocyte counts and hematocrits.

This mRNA is capped using CleanCap® Reagent M6, TriLink's patented co-transcriptional capping technology, resulting in the naturally occurring Cap-1 structure with >95% capping efficiency. It is polyadenylated, modified with N1-methylpseudouridine, and optimized for mammalian systems. It mimics a fully processed mature mRNA.

CleanCap® Reagent M6, otherwise known as CleanCap® m6AG 3'OMe, produces a base-modified Cap-1 mRNA, which shows superior *in vivo* activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA). CleanCap® Reagent M6 may further increase protein expression relative to previous generations of cap analogs, such as CleanCap® AG or CleanCap® AG (3'OMe), or mRNAs produced by enzymatic capping strategies¹.

N1-methylpseudouridine is a modified uridine that can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression.

Full length: 859 nucleotides
ORF Length: 598 nucleotides

ORF sequence available online at trilinkbiotech.com/cleancap-m6-epo-mrna-n1mepsu.html

CleanCap® M6 EPO mRNA (N1MePsU)* may be ordered using the following catalog numbers:

L-8109-100 (100 µg)
L-8109-1000 (1 mg)
L-8109-5 (5 x 1 mg)
L-8109-BK (Bulk amount)

1.0 mg/mL in 1 mM sodium citrate, pH 6.4

Store at or below -40°C.

Use & handling

Store at or below -40°C. Thaw and work on ice. Upon first use, pulse spin before opening and aliquot into single-use portions. Do not vortex. Use only certified RNase-free reagents and consumables with proper RNase-free technique. Use of barrier tips is recommended. Avoid freeze/thaw cycles. Do not mix with media containing serum unless first complexed with a stabilizing transfection reagent.

QC analysis

- A260/A280 ratio
- dsRNA
- Concentration
- Fragment analyzer
- Agarose gel mobility
- Capping efficiency

A standard conversion factor of 40 µg/OD260 was used to calculate quantity.

Product released by Quality Assurance. TriLink is certified ISO 9001:2015.

Troubleshooting

For any questions or technical support around this product, please reach out to support@trilinkbiotech.com

¹Final capping is dependent upon the CleanCap® Reagent, DNA template, and final mRNA sequence. Secondary structure due to RNA length and base composition can affect final capping efficiency, mRNA yield, and translation efficiency.

Related TriLink and Alphazyme products

CleanCap® M6 EGFP mRNA (N1MePsU) (cat no. L-8101)**
CleanCap® M6 FLuc mRNA (N1MePsU) (cat no. L-8102)*
CleanCap® M6 mCherry mRNA (N1MePsU) (cat no. L-8103)*
CleanCap® M6 Cas9 mRNA (N1MePsU) (cat no. L-8106)*§
CleanCap® M6 Cre mRNA (N1MePsU) (cat no. L-8111)*

CleanCap® OVA mRNA (cat no. L-7610)
CleanCap® beta gal mRNA (cat no. L-7608)
CleanCap® Cas9 mRNA (cat no. L-7606)§
CleanCap® FLuc mRNA (cat no. L-7602)
CleanCap® EGFP mRNA (cat no. L-7601)‡

CleanCap® Cre mRNA (5moU) (cat no. L-7211)
CleanCap® OVA mRNA (5moU) (cat no. L-7210)
CleanCap® EPO mRNA (5moU) (cat no. L-7209)
CleanCap® beta gal mRNA (5moU) (cat no. L-7208)
CleanCap® Cas9 Nickase mRNA (5moU) (cat no. L-7207)§
CleanCap® Cas9 mRNA (5moU) (cat no. L-7206)§
CleanCap® Renilla Luc mRNA (5moU) (cat no. L-7204)
CleanCap® mCherry mRNA (5moU) (cat no. L-7203)

CleanCap® Fluc mRNA (5moU) (cat no. L-7202)
CleanCap® EGFP mRNA (5moU) (cat no. L-7201)‡

CleanCap® Reagent M6 (cat. no. N-7453)
CleanCap® Reagent AG (cat. no. N-7113)
CleanCap® Reagent AG (3' OMe) (cat. no. N-7413)
CleanCap® Reagent AU (cat. no. N-7114)

N1-Methylpseudouridine-5'-Triphosphate (cat. No. N-1081)*
5-Methoxyuridine-5'-Triphosphate (cat. no. N-1093)
Pseudouridine-5'-Triphosphate (cat. No. N-1019)
Nucleoside-5'-Triphosphate (NTP) Set (cat. no. N-1505)
Adenosine-5'-Triphosphate, ATP (cat. no. N-1501)
Cytidine-5'-Triphosphate, CTP (cat. no. N-1502)
Guanosine-5'-Triphosphate, GTP (cat. no. N-1503)
Uridine-5'-Triphosphate, UTP (cat. no. N-1504)

T7 RNA Polymerase (Alphazyme cat. No E057)
Inorganic Pyrophosphatase (E. coli) (Alphazyme cat. No E051)
Engineered RNase Inhibitor (Alphazyme cat. No E075)

Related TriLink services

TriLink offers RUO and GMP custom CleanCap® Cap-1 mRNA production services in addition to our catalog mRNA offerings. Visit our website trilinkbiotech.com/mrna-cdmo-services or contact us at mrna-services@trilinkbiotech.com for more information.

Products containing CleanCap® technology are for internal research use only. A license is required for commercial use of CleanCap® Reagent M6 and other CleanCap® Products. For license restrictions and patent(s) information, refer to the Research License Agreement below.

*Nothing herein shall be deemed to constitute the grant of any license or other right in respect of any third-party rights in relation to the use of any materials or products controlled by a third party, and no license, sublicense or other rights shall be created hereunder by implication, estoppel or otherwise in or to any such third-party rights.

§CleanCap® M6 Cas9 mRNA (N1MePsU), CleanCap® Cas9 mRNA (5moU), and CleanCap® Cas9 Nickase mRNA (5moU), CleanCap® Cas9 mRNA, and/or other products or technologies relating to the Cas System (collectively, the "Cas Products") are provided under a Limited License granted by the Broad Institute, the Massachusetts Institute of Technology, President and Fellows of Harvard College, University of Iowa, University of Tokyo and Rockefeller University to the Buyer of the Cas Products, conveying to the Limited Licensee the non-transferrable right to use the purchased amount of the Cas Products solely for internal, non-clinical research to be conducted by the Limited Licensee found in trilinkbiotech.com/legal-notices

‡EGFP products are sold with a Limited Use Label License under sublicense with Life Technologies, Inc. Please review Limited License at trilinkbiotech.com/gfp-label-license.

CleanCap® products | Research license agreement

trilinkbiotech.com/cleancap-research-license

PURCHASE AND/OR USE OF THIS PRODUCT SHALL CONSTITUTE ACKNOWLEDGMENT AND ACCEPTANCE OF THESE TERMS AND CONDITIONS.

Products containing the CleanCap technology (hereinafter “Products”) and their use may be covered by one or more patents or pending Patent Applications. If Buyer does not agree to use the Products purchased pursuant to the terms and conditions set out in this Research License Agreement (“Agreement”), the Buyer should contact TriLink BioTechnologies, LLC within ten days of receipt to return the unused and unopened Products for a full refund; provided, however, that custom-made Products may not be returned for a refund.

- 1. Research Use.** The purchase of Products containing CleanCap conveys to the buyer a non-exclusive, non-transferrable right to use the purchased amount of Products in internal research conducted by the buyer, whether the buyer is an academic, non-profit, or for-profit entity. Buyer agrees that it will not sell or otherwise transfer Products, or any components or derivatives thereof, to any third party. Notwithstanding the foregoing, materials made through use of the Products may be transferred by Buyer to Buyer’s legal affiliates or bona fide third party contractors performing paid work on Buyer’s behalf, provided the use by such third party contractors is limited to performance of work for Buyer and such work is performed subject to the terms of this Agreement.
- 2. Commercial Use.** Buyer also agrees that it will not sell, transfer, or otherwise use Products, or any components or derivatives thereof, for any commercial purposes, including (a) any human, clinical or clinical trial use, including, without limitation, any administration into humans or any diagnostic or prognostic use; (b) any human germline modification, including modifying the DNA of human embryos or human reproductive cells; (c) any in vivo veterinary or livestock use; (d) the development, manufacture, distribution, importation, exportation, transportation, sale, offer for sale, marketing, promotion or other exploitation or use of the Patent Rights or a Product for or as a testing service, therapeutic or diagnostic for humans or animals; (e) Products that provide nutritional benefits and are regulated by a regulatory authority as a drug or biologic pursuant to Section 505 of the Federal Food, Drug, and Cosmetic Act of 1938, as amended, Section 351 of the Public Health Service Act of 1944, as amended, or any successor laws, or equivalent laws or regulations in jurisdictions outside the United States; (f) any agricultural use, including but not limited to the use or application in the cultivation, growth, manufacture, exportation, or production of any tobacco product; and (g) any use or application relating to gene drive, unless and until a license is obtained for such commercial use of Products, components, or derivatives thereof, regardless of the academic or non-profit status of the using entity. Information about commercial licenses for Products may be obtained by contacting TriLink BioTechnologies, LLC. Buyer may not use the Products to support the filing of a patent application that contains claims directed to the Products or uses thereof in any country in the world without the express approval of TriLink BioTechnologies, LLC.
- 3. Attribution.** Buyers of the Products will expressly refer to the provision of the Products in their published and unpublished works by explicitly identifying the Products purchased and stating that the Products were “purchased from TriLink BioTechnologies, LLC (www.trilinkbiotech.com).”
- 4. Warranty.** The Products are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, express or implied, and without any representation or warranty that the use or supply of the Products will not infringe any patent, copyright, trademark or other right. TriLink BioTechnologies, LLC does not recommend to its end users any particular application, methodology and/or protocol for the use of the Products. Depending on Buyer’s particular use of the Products, it may be necessary to obtain a separate license or licenses from one or more third parties.
- 5. Limitation of Liability.** TriLink BioTechnologies, LLC and its employees and agents shall not be held liable for your use of the Products transferred to you. Buyer agrees to hold TriLink BioTechnologies, LLC and its employees and agents harmless for any loss, claim, damage or liability, of whatsoever kind or nature, which may arise from acceptance, use, handling or storage of the Products by Buyer. In no event shall buyer be entitled to recover from TriLink BioTechnologies, LLC any special, indirect, incidental, consequential, or punitive damages in connection with this agreement, buyer’s use of the Products, or the license granted hereunder.
- 6. Regulation Compliance.** Upon receipt of Products, buyer shall use its expertise and facilities in strict compliance with all applicable local, state and federal laws, regulations and guidelines. Buyer understands that the Products may have biological and/or chemical properties that are unpredictable and unknown at the time of transfer, that they are to be used with caution and prudence, and that they will not to be used for testing in, or treatment of, humans.
- 7. Termination.** Your right to have and use the Products will terminate immediately if Buyer fails to comply with the terms and conditions of this Agreement. Upon such termination of rights, Buyer shall destroy all Products, or any components or derivatives thereof, and notify TriLink BioTechnologies, LLC of such in writing.
- 8. Miscellaneous.** This Agreement sets forth the complete and entire agreement of the Parties with respect to the subject matter hereof and supersedes and terminates all prior agreements and understandings between the Parties. No subsequent amendment or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties. This Agreement shall not be assigned or otherwise transferred by the buyer.